文献速递膀胱癌与上尿路尿路上皮癌

AUA风险分层对高级别Ta非肌层浸润性膀胱癌卡介苗与吉西他滨/多西他赛灌注疗效的影响

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2026-01-19

该回顾性队列纳入128例初治高级别Ta非肌层浸润性膀胱癌患者,比较膀胱内灌注卡介苗(BCG,n=65)与吉西他滨/多西他赛(Gem/Doce,n=63)的肿瘤学结局。Gem/Doce组24个月无进展生存率为100%,BCG组为91%;AUA风险分层(中危 vs 高危)与复发结局无显著关联,Gem/Doce不良事件发生率低于BCG(40% vs 46%)。

要点

  • Gem/Doce组24个月无进展生存率100%,BCG组91%。
  • AUA风险分层(中危 vs 高危)与无复发生存无显著关联(HR 1.05,P=0.89)。
  • Gem/Doce不良事件发生率低于BCG(40% vs 46%),且无III级事件。

核心结论

  • Gem/Doce是高级别Ta NMIBC耐受良好且有效的BCG替代方案。
  • 在该亚组中,AUA风险分层(中危 vs 高危)与复发结局无显著关联,需前瞻性验证。

研究设计与样本

  • 回顾性队列研究,纳入2011年1月至2024年12月治疗的128例初治高级别Ta NMIBC患者。
  • 患者经切除后接受BCG(n=65)或Gem/Doce(n=63)膀胱内灌注,Gem/Doce采用24个月维持方案,BCG在3、9、15个月给药。
  • 采用Cox回归模型评估患者、疾病和治疗特征对肿瘤学结局的影响。

主要发现

  • BCG组随访时间(中位[IQR] 81[44-113]个月)长于Gem/Doce组(中位[IQR] 37[26-55]个月)。
  • Gem/Doce组12和24个月无复发生存率分别为80%和76%,BCG组分别为76%和70%。
  • Gem/Doce组12和24个月高级别无复发生存率分别为82%和78%,BCG组分别为79%和75%。
  • 24个月无进展生存率Gem/Doce组为100%,BCG组为91%。
  • AUA风险分类(中危 vs 高危)与无复发生存(HR 1.05,P=0.89)和高级别无复发生存(HR 1.12,P=0.75)无显著关联;治疗类型(BCG vs Gem/Doce)与无复发生存(HR 1.19,P=0.60)和高级别无复发生存(HR 1.02,P=0.96)也无显著关联。

临床怎么用

  • 对于高级别Ta NMIBC,Gem/Doce可作为BCG的耐受良好且有效的替代灌注方案。
  • AUA风险分层(中危 vs 高危)在该亚组中未显示与复发结局的显著关联,临床决策需结合其他因素。

局限性

  • 回顾性研究设计。
  • BCG组随访时间明显长于Gem/Doce组。
  • AUA风险分层与复发结局的关联需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare oncological outcomes between intravesical bacillus Calmette-Guérin (BCG) and gemcitabine/docetaxel (Gem/Doce) in patients with primary high-grade (HG) Ta non-muscle-invasive bladder cancer (NMIBC) and assess the prognostic utility of the American Urological Association (AUA) risk stratification system, which classifies these tumours as intermediate risk (IR) or high risk (HR). PATIENTS AND METHODS: Retrospective cohort of 128 treatment-naïve patients with HG Ta NMIBC treated from January 2011 to December 2024 was analysed. After resection, patients received intravesical therapy with either BCG (n = 65) or Gem/Doce (n = 63), with Gem/Doce on a 24-month maintenance schedule and BCG at 3, 9, and 15 months. Cox regression models evaluated the impact of patient, disease, and treatment characteristics on oncological outcomes. RESULTS: The follow-up was longer in the BCG group (median [interquartile range, IQR] 81 [44-113] months) than in the Gem/Doce group (median [IQR] 37 [26-55] months). Recurrence-free survival (RFS) at 12 and 24 months was 80% and 76% for Gem/Doce, and 76% and 70% for BCG, respectively. HG-RFS at 12 and 24 months was 82% and 78% for Gem/Doce, and 79% and 75% for BCG, respectively. The 24-month progression-free survival was 100% for Gem/Doce and 91% for BCG. There were no significant associations between AUA risk classification (IR vs HR; hazard ratio 1.05, P = 0.89 for RFS; hazard ratio 1.12, P = 0.75 for HG-RFS) or treatment type (BCG vs Gem/Doce; hazard ratio 1.19, P = 0.60 for RFS; hazard ratio 1.02, P = 0.96 for HG-RFS) and recurrence outcomes. Adverse events were less frequent with Gem/Doce than BCG (40% vs 46%), with no Grade III events in the Gem/Doce group. CONCLUSION: Treatment with Gem/Doce is a well-tolerated, effective alternative to BCG for HG Ta NMIBC. In this subset, AUA risk stratification (IR vs HR) was not significantly associated with recurrence outcomes, warranting prospective validation.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Abou Chakra M, McElree IM, Mott SL, et al. Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer. BJU Int. 2026. PMID: 41552893. doi:10.1111/bju.70149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。